122 related articles for article (PubMed ID: 36924677)
1. Histone methyltransferase KMT2D promotes prostate cancer progression through paracrine IL-6 signaling.
Zhang J; Ye Y; Xu Z; Luo M; Wu C; Zhang Y; Lv S; Wei Q
Biochem Biophys Res Commun; 2023 May; 655():35-43. PubMed ID: 36924677
[TBL] [Abstract][Full Text] [Related]
2. Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3.
Lv S; Wen H; Shan X; Li J; Wu Y; Yu X; Huang W; Wei Q
Epigenetics; 2019 Dec; 14(12):1194-1208. PubMed ID: 31232159
[TBL] [Abstract][Full Text] [Related]
3. TUG1 promotes the development of prostate cancer by regulating RLIM.
Guo BH; Zhao Q; Li HY
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):1926-1933. PubMed ID: 30915735
[TBL] [Abstract][Full Text] [Related]
4. Histone methyltransferase SUV39H2 regulates apoptosis and chemosensitivity in prostate cancer through AKT/FOXO signaling pathway.
Sun D; Guo J; Liang W; Chen Y; Wei S; Li A; Wang L; Chen X
Med Oncol; 2024 Jan; 41(2):44. PubMed ID: 38170382
[TBL] [Abstract][Full Text] [Related]
5. Histone Methyltransferase KMT2D Regulates H3K4 Methylation and is Involved in the Pathogenesis of Ovarian Cancer.
Li M; Shi M; Xu Y; Qiu J; Lv Q
Cell Transplant; 2021; 30():9636897211027521. PubMed ID: 34705580
[TBL] [Abstract][Full Text] [Related]
6. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
[TBL] [Abstract][Full Text] [Related]
7. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
[TBL] [Abstract][Full Text] [Related]
8. Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
Lv S; Ji L; Chen B; Liu S; Lei C; Liu X; Qi X; Wang Y; Lai-Han Leung E; Wang H; Zhang L; Yu X; Liu Z; Wei Q; Lu L
Oncogene; 2018 Mar; 37(10):1354-1368. PubMed ID: 29269867
[TBL] [Abstract][Full Text] [Related]
9. CircLRP6 contributes to prostate cancer growth and metastasis by binding to miR-330-5p to up-regulate NRBP1.
Qin L; Sun X; Zhou F; Liu C
World J Surg Oncol; 2021 Jun; 19(1):184. PubMed ID: 34158077
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.
Chen H; Tu SW; Hsieh JT
J Biol Chem; 2005 Jun; 280(23):22437-44. PubMed ID: 15817459
[TBL] [Abstract][Full Text] [Related]
11. Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells.
Chen Y; Pan C; Wang X; Xu D; Ma Y; Hu J; Chen P; Xiang Z; Rao Q; Han X
Theranostics; 2021; 11(16):7640-7657. PubMed ID: 34335955
[No Abstract] [Full Text] [Related]
12. Downregulation of KMT2D suppresses proliferation and induces apoptosis of gastric cancer.
Xiong W; Deng Z; Tang Y; Deng Z; Li M
Biochem Biophys Res Commun; 2018 Sep; 504(1):129-136. PubMed ID: 30177394
[TBL] [Abstract][Full Text] [Related]
13. SP1-mediated upregulation of lncRNA SNHG4 functions as a ceRNA for miR-377 to facilitate prostate cancer progression through regulation of ZIC5.
Wang ZY; Duan Y; Wang P
J Cell Physiol; 2020 Apr; 235(4):3916-3927. PubMed ID: 31608997
[TBL] [Abstract][Full Text] [Related]
14. Histone methyltransferase KMT2D inhibits ENKTL carcinogenesis by epigenetically activating SGK1 and SOCS1.
Zhang YH; Tao Q; Zhang WY; Zhao S; Liu WP; Gao LM
Genes Genomics; 2024 Feb; 46(2):203-212. PubMed ID: 37523130
[TBL] [Abstract][Full Text] [Related]
15. TERF1 downregulation promotes the migration and invasion of the PC3 prostate cancer cell line as a target of miR‑155.
Chen W; He LN; Liang Y; Zeng X; Wu CP; Su MQ; Cheng Y; Liu JH
Mol Med Rep; 2020 Dec; 22(6):5209-5218. PubMed ID: 33174061
[TBL] [Abstract][Full Text] [Related]
16. Histone methyltransferase KMT2D mediated lipid metabolism via peroxisome proliferator-activated receptor gamma in prostate cancer.
Zhai Q; Luo M; Zhang Y; Zhang W; Wu C; Lv S; Wei Q
Transl Cancer Res; 2022 Aug; 11(8):2607-2621. PubMed ID: 36093518
[TBL] [Abstract][Full Text] [Related]
17. The interleukin 6 receptor is a direct transcriptional target of E2F3 in prostate tumor derived cells.
Libertini SJ; Chen H; al-Bataina B; Koilvaram T; George M; Gao AC; Mudryj M
Prostate; 2012 May; 72(6):649-60. PubMed ID: 21837779
[TBL] [Abstract][Full Text] [Related]
18. SIRT7 depletion inhibits cell proliferation and androgen-induced autophagy by suppressing the AR signaling in prostate cancer.
Ding M; Jiang CY; Zhang Y; Zhao J; Han BM; Xia SJ
J Exp Clin Cancer Res; 2020 Feb; 39(1):28. PubMed ID: 32019578
[TBL] [Abstract][Full Text] [Related]
19.
Wang R; He Y; Wang Y; Xie S
Front Biosci (Landmark Ed); 2023 Jan; 28(1):17. PubMed ID: 36722273
[TBL] [Abstract][Full Text] [Related]
20. MiR-492 exerts tumor-promoting function in prostate cancer through repressing SOCS2 expression.
Shi LP; Liang M; Li FF; Li T; Lai DH; Xie QL; Yin YF; Liu YF
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):992-1001. PubMed ID: 30779065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
